Department of Allergy and Immunology, University of California, San Diego, La Jolla, Calif 92111, USA.
J Allergy Clin Immunol. 2011 Nov;128(5):964-9. doi: 10.1016/j.jaci.2011.06.031. Epub 2011 Aug 6.
The association between obesity and asthma severity and control in children is not well understood.
The objective of this study was to examine the association of childhood body mass index (BMI) percentile for age of 85% or greater with the number of β-agonist canisters dispensed, corticosteroid courses, emergency department visits, and hospitalizations for asthma.
A retrospective cohort of 32,321 children aged 5 to 17 years and given a diagnosis of asthma who received at least 1 asthma (controller or rescue) medication and were enrolled in Kaiser Permanente from 2004-2008 was identified. Outcomes from electronic medical records included β-agonist canister and nebulizer units dispensed per year, hospitalizations and emergency department visits for asthma exacerbations, and oral corticosteroid courses. Potential confounding factors known to influence asthma outcomes were also collected: demographics, parental education level, asthma controller use, gastroesophageal reflux disease diagnosis, and diabetes mellitus diagnosis. Multiple logistic regression models were used to measure the independent association of BMI status with outcomes.
Even after adjusting for demographics, parental education level, asthma controller use, and gastroesophageal reflux disease and diabetes mellitus diagnoses, overweight (BMI percentile for age, 85% to 94%) and obese (BMI percentile for age, ≥ 95%) children were more likely to have increased β-agonists dispensed (odds ratio of 1.15 [95% CI, 1.02-1.27] and odds ratio of 1.17 [95% CI, 1.06-1.29], respectively) and increased risk for oral corticosteroids dispensed (odds ratio of 1.21 [95% CI, 1.13-1.29] and odds ratio of 1.28 [95% CI, 1.21-1.36], respectively) compared with normal-weight (BMI percentile for age, 16% to 84%) children.
Our findings suggest that childhood obesity is associated with an increased risk of worse asthma control and exacerbations.
肥胖与儿童哮喘严重程度和控制之间的关系尚不清楚。
本研究旨在研究儿童体重指数(BMI)年龄百分位值为 85%或更高与β-激动剂用量、皮质类固醇疗程、急诊就诊和哮喘住院次数之间的关系。
回顾性队列研究纳入了 2004-2008 年在 Kaiser Permanente 接受至少 1 种哮喘(控制或缓解)药物治疗并被诊断为哮喘的 32321 名 5 至 17 岁的儿童。从电子病历中获得的结果包括每年β-激动剂用量和雾化器用量、哮喘加重的住院和急诊就诊次数以及口服皮质类固醇疗程。还收集了已知影响哮喘结果的潜在混杂因素:人口统计学、父母教育水平、哮喘控制药物使用、胃食管反流病诊断和糖尿病诊断。采用多变量逻辑回归模型来衡量 BMI 状况与结果之间的独立关联。
即使在调整了人口统计学、父母教育水平、哮喘控制药物使用以及胃食管反流病和糖尿病诊断等因素后,超重(BMI 年龄百分位值为 85%至 94%)和肥胖(BMI 年龄百分位值为≥95%)儿童使用β-激动剂的可能性更高(比值比分别为 1.15[95%CI,1.02-1.27]和 1.17[95%CI,1.06-1.29]),使用口服皮质类固醇的风险也更高(比值比分别为 1.21[95%CI,1.13-1.29]和 1.28[95%CI,1.21-1.36])与体重正常(BMI 年龄百分位值为 16%至 84%)的儿童相比。
我们的研究结果表明,儿童肥胖与哮喘控制和恶化风险增加有关。